{"title":"日本2019冠状病毒病期间结直肠癌筛查:来自2021-2022 JACSIS研究的分析","authors":"Hiroaki Saito, Aminu Kende Abubakar, Akihiko Ozaki, Daisuke Hori, Michio Murakami, Yudai Kaneda, Masaharu Tsubokura, Takahiro Tabuchi","doi":"10.1002/cam4.70859","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Maintaining a high participation rate is crucial for effective colorectal cancer (CRC) screening. The COVID-19 pandemic placed a significant burden on healthcare facilities, which hindered CRC screening efforts. However, the effects of the prolonged pandemic on CRC screening remain unclear.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We analyzed data from the Japan COVID-19 and Society Internet Survey in September 2021 and 2022 to examine CRC screening participation over the past year. We also evaluated the association between CRC screening participation in 2022 and the participation status, future screening intentions, background characteristics, and anxiety about COVID-19 measured using the fear of coronavirus disease 2019 scale (FVC-19S) from the 2021 survey..</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 13,261 respondents, 40.5% reported undergoing CRC screening in 2021, while 48.7% did so in 2022. Multivariable Poisson regression analysis showed that significant factors associated with CRC screening participation in 2022 included being male (adjusted incidence risk ratio [aIRR] 1.07, 95% confidence interval [CI]; 1.00–1.14, <i>p</i> = 0.026), age in the 40s (aIRR 0.89, 95% CI; 0.81–0.97, <i>p</i> = 0.012) and 50s (aIRR 0.89, 95% CI; 0.82–0.98, <i>p</i> = 0.011), being unmarried (aIRR 0.88, 95% CI; 0.82–0.95, <i>p</i> = 0.001), and employment status such as self-employed (aIRR 0.86, 95% CI; 0.76–0.97, <i>p</i> = 0.012) or unemployed (aIRR 0.86, 95% CI; 0.81–0.92, <i>p</i> < 0.01). Having an FVC-19S score below 21 was also a factor (aIRR 0.95, 95% CI; 0.90–1.00, <i>p</i> = 0.032).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Although CRC screening rates increased from 2021 to 2022, a significant proportion of respondents still reported not undergoing screening, highlighting the importance of assessing the long-term impact of COVID-19 and identifying factors that make screening less accessible.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70859","citationCount":"0","resultStr":"{\"title\":\"Colorectal Cancer Screening Amid COVID-19 in Japan: Analysis From the 2021–2022 JACSIS Study\",\"authors\":\"Hiroaki Saito, Aminu Kende Abubakar, Akihiko Ozaki, Daisuke Hori, Michio Murakami, Yudai Kaneda, Masaharu Tsubokura, Takahiro Tabuchi\",\"doi\":\"10.1002/cam4.70859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Maintaining a high participation rate is crucial for effective colorectal cancer (CRC) screening. The COVID-19 pandemic placed a significant burden on healthcare facilities, which hindered CRC screening efforts. However, the effects of the prolonged pandemic on CRC screening remain unclear.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We analyzed data from the Japan COVID-19 and Society Internet Survey in September 2021 and 2022 to examine CRC screening participation over the past year. We also evaluated the association between CRC screening participation in 2022 and the participation status, future screening intentions, background characteristics, and anxiety about COVID-19 measured using the fear of coronavirus disease 2019 scale (FVC-19S) from the 2021 survey..</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Of the 13,261 respondents, 40.5% reported undergoing CRC screening in 2021, while 48.7% did so in 2022. Multivariable Poisson regression analysis showed that significant factors associated with CRC screening participation in 2022 included being male (adjusted incidence risk ratio [aIRR] 1.07, 95% confidence interval [CI]; 1.00–1.14, <i>p</i> = 0.026), age in the 40s (aIRR 0.89, 95% CI; 0.81–0.97, <i>p</i> = 0.012) and 50s (aIRR 0.89, 95% CI; 0.82–0.98, <i>p</i> = 0.011), being unmarried (aIRR 0.88, 95% CI; 0.82–0.95, <i>p</i> = 0.001), and employment status such as self-employed (aIRR 0.86, 95% CI; 0.76–0.97, <i>p</i> = 0.012) or unemployed (aIRR 0.86, 95% CI; 0.81–0.92, <i>p</i> < 0.01). Having an FVC-19S score below 21 was also a factor (aIRR 0.95, 95% CI; 0.90–1.00, <i>p</i> = 0.032).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Although CRC screening rates increased from 2021 to 2022, a significant proportion of respondents still reported not undergoing screening, highlighting the importance of assessing the long-term impact of COVID-19 and identifying factors that make screening less accessible.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 8\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70859\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70859\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70859","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景保持高参与率是有效的结直肠癌(CRC)筛查的关键。COVID-19大流行给医疗机构带来了沉重负担,阻碍了结直肠癌筛查工作。然而,长期大流行对CRC筛查的影响尚不清楚。方法分析日本2021年9月和2022年9月的COVID-19和社会互联网调查数据,检查过去一年的CRC筛查参与情况。我们还评估了2022年参与CRC筛查与参与状况、未来筛查意图、背景特征和对COVID-19的焦虑之间的关系,这些焦虑是使用2021年调查中的冠状病毒疾病恐惧2019量表(FVC-19S)测量的。在13261名受访者中,40.5%的人报告在2021年接受了CRC筛查,而48.7%的人在2022年接受了筛查。多变量泊松回归分析显示,2022年参与CRC筛查的显著因素包括男性(调整发病率风险比[aIRR] 1.07, 95%可信区间[CI];1.00-1.14, p = 0.026),年龄在40多岁(aIRR 0.89, 95% CI;0.81-0.97, p = 0.012)和50 (aIRR 0.89, 95% CI;0.82-0.98, p = 0.011),未婚(aIRR 0.88, 95% CI;0.82-0.95, p = 0.001),就业状况如自雇(aIRR 0.86, 95% CI;0.76-0.97, p = 0.012)或失业(aIRR 0.86, 95% CI;0.81-0.92, p < 0.01)。FVC-19S评分低于21也是一个因素(aIRR 0.95, 95% CI;0.90-1.00, p = 0.032)。尽管从2021年到2022年,结直肠癌筛查率有所上升,但仍有很大比例的受访者表示未接受筛查,这凸显了评估COVID-19的长期影响和确定导致筛查难以获得的因素的重要性。
Colorectal Cancer Screening Amid COVID-19 in Japan: Analysis From the 2021–2022 JACSIS Study
Background
Maintaining a high participation rate is crucial for effective colorectal cancer (CRC) screening. The COVID-19 pandemic placed a significant burden on healthcare facilities, which hindered CRC screening efforts. However, the effects of the prolonged pandemic on CRC screening remain unclear.
Methods
We analyzed data from the Japan COVID-19 and Society Internet Survey in September 2021 and 2022 to examine CRC screening participation over the past year. We also evaluated the association between CRC screening participation in 2022 and the participation status, future screening intentions, background characteristics, and anxiety about COVID-19 measured using the fear of coronavirus disease 2019 scale (FVC-19S) from the 2021 survey..
Results
Of the 13,261 respondents, 40.5% reported undergoing CRC screening in 2021, while 48.7% did so in 2022. Multivariable Poisson regression analysis showed that significant factors associated with CRC screening participation in 2022 included being male (adjusted incidence risk ratio [aIRR] 1.07, 95% confidence interval [CI]; 1.00–1.14, p = 0.026), age in the 40s (aIRR 0.89, 95% CI; 0.81–0.97, p = 0.012) and 50s (aIRR 0.89, 95% CI; 0.82–0.98, p = 0.011), being unmarried (aIRR 0.88, 95% CI; 0.82–0.95, p = 0.001), and employment status such as self-employed (aIRR 0.86, 95% CI; 0.76–0.97, p = 0.012) or unemployed (aIRR 0.86, 95% CI; 0.81–0.92, p < 0.01). Having an FVC-19S score below 21 was also a factor (aIRR 0.95, 95% CI; 0.90–1.00, p = 0.032).
Conclusions
Although CRC screening rates increased from 2021 to 2022, a significant proportion of respondents still reported not undergoing screening, highlighting the importance of assessing the long-term impact of COVID-19 and identifying factors that make screening less accessible.
期刊介绍:
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.